Maspin mediates the gemcitabine sensitivity of hormone-independent prostate cancer

Medicine and Dentistry

• Prostate Cancer 100%
• Gemcitabine 100%
• Maspin 100%
• B-Cell Lymphoma 33%
• Programmed Cell Death 26%
• Cancer Cell 13%
• Combination Therapy 13%
• Western Blot 13%
• Myeloid Cell 13%
• Androgen 13%
• Leukemia 13%
• Disease 6%
• Neoplasm 6%
• Cancer Therapy 6%
• Cell Death 6%
• Short Hairpin RNA 6%
• Promoter Region 6%
• Real Time Polymerase Chain Reaction 6%
• Flow Cytometry 6%
• Lipocortin 5 6%
• MTT Assay 6%
• Ablation Therapy 6%
• Serine Proteinase Inhibitor 6%
• Biphenyl 6%
• Androgen Deprivation Therapy 6%
• Tetrazolium 6%
• Apoptosis Assay 6%
• Castration Resistant Prostate Cancer 6%
• Molecularly Targeted Therapy 6%
• Cytotoxicity 6%
• Propidium Iodide 6%

Pharmacology, Toxicology and Pharmaceutical Science

• Prostate Cancer 100%
• Maspin 100%
• Gemcitabine 100%
• B Cell Lymphoma 33%
• Androgen 20%
• Western Blot 13%
• Leukemia 13%
• Combination Therapy 13%
• Cytotoxicity 6%
• Malignant Neoplasm 6%
• Short Hairpin RNA 6%
• Tetrazolium 6%
• Flow Cytometry 6%
• Propidium Iodide 6%
• Lipocortin 5 6%
• Apoptosis Assay 6%
• Biphenyl 6%
• Serine Proteinase Inhibitor 6%
• Castration Resistant Prostate Cancer 6%
• Disease 6%
• Neoplasm 6%

Biochemistry, Genetics and Molecular Biology

• Gemcitabine 100%
• Maspin 100%
• B Cell 33%
• Cancer Cell 13%
• Myeloid 13%
• Western Blot 13%
• Promoter Region 6%
• Flow Cytometry 6%
• Real-Time Polymerase Chain Reaction 6%
• Propidium Iodide 6%
• Apoptosis Assay 6%
• Serine Protease Inhibitor 6%
• Cell Death 6%
• Cytotoxicity 6%
• Small Hairpin RNA 6%
• Annexin 6%
• MTT Assay 6%